Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
Behav Pharmacol ; 28(4): 313-317, 2017 06.
Article in English | MEDLINE | ID: mdl-27922541

ABSTRACT

As pupil size is affected by psychotropic drugs in all mammals, it has been used as a well-established clinical indicator for the preclinical and clinical development of novel drugs. It has been reported that activation of the serotonin (5-HT)1A receptor differently affects pupil response in rodents (mydriasis) and humans (miosis). Thus, it is important to establish a quantitative system for measuring pupil size using other species, such as nonhuman primates. Common marmosets have recently attracted a great deal of attention as suitable experimental animals in the psychoneurological field because of handling ease compared with other nonhuman primates and the requirement for small amounts of test drugs. In this study, we constructed a system for measuring changes in pupil size using an infrared eye-tracking camera and evaluated the effects on pupil size of the 5-HT1A receptor agonists buspirone, 8-OH-DPAT and buspirone active metabolite 1-(2-pyrimidinyl) piperazine. Our results show that both buspirone and 8-OH-DPAT significantly decrease pupil size in a dose-dependent manner. The 5-HT1A receptor antagonist WAY 100635 completely blocked both buspirone and 8-OH-DPAT-induced miosis, whereas 1-(2-pyrimidinyl) piperazine had no effect on pupil size. These results suggest that measurement of pupil size may be a useful biomarker for predicting the pharmacodynamics of new 5-HT1A receptor agonists.


Subject(s)
8-Hydroxy-2-(di-n-propylamino)tetralin/pharmacology , Buspirone/pharmacology , Pupil/drug effects , Serotonin 5-HT1 Receptor Agonists/pharmacology , 8-Hydroxy-2-(di-n-propylamino)tetralin/administration & dosage , Animals , Buspirone/administration & dosage , Callithrix , Dose-Response Relationship, Drug , Female , Infrared Rays , Male , Piperazines/pharmacology , Pyridines/pharmacology , Serotonin 5-HT1 Receptor Agonists/administration & dosage
2.
Psychopharmacology (Berl) ; 233(21-22): 3673-3684, 2016 Oct.
Article in English | MEDLINE | ID: mdl-27530989

ABSTRACT

RATIONALE: There is a significant interest in the NMDA-receptor antagonist ketamine due to its efficacy in treating depressive disorders and its induction of psychotic-like symptoms that make it a useful tool for modeling psychosis. Pharmacological MRI in awake nonhuman primates provides a highly translational model for studying the brain network dynamics involved in producing these drug effects. OBJECTIVE: The present study evaluated ketamine-induced changes in functional connectivity (FC) in awake rhesus monkeys. The effects of ketamine after pretreatment with the antipsychotic drug risperidone were also examined. METHODS: Functional MRI scans were conducted in four awake adult female rhesus monkeys during sub-anesthetic i.v. infusions of ketamine (0.345 mg/kg bolus followed by 0.256 mg kg-1 h-1 constant infusion) with and without risperidone pretreatment (0.06 mg/kg). A 10-min window of stable BOLD signal was used to compare FC between baseline and drug conditions. FC was assessed in specific regions of interest using seed-based cross-correlation analysis. RESULTS: Ketamine infusion induced extensive changes in FC. In particular, FC to the dorsolateral prefrontal cortex (dlPFC) was increased in several cortical and subcortical regions. Pretreatment with risperidone largely attenuated ketamine-induced changes in FC. CONCLUSIONS: The results are highly consistent with similar human imaging studies showing ketamine-induced changes in FC, as well as a significant attenuation of these changes when ketamine infusion is preceded by pretreatment with risperidone. The extensive increases shown in FC to the dlPFC are consistent with the idea that disinhibition of the dlPFC may be a key driver of the antidepressant and psychotomimetic effects of ketamine.


Subject(s)
Brain/drug effects , Excitatory Amino Acid Antagonists/pharmacology , Ketamine/pharmacology , Animals , Antipsychotic Agents/pharmacology , Brain/diagnostic imaging , Female , Functional Neuroimaging , Macaca mulatta , Magnetic Resonance Imaging , Prefrontal Cortex/diagnostic imaging , Prefrontal Cortex/drug effects , Risperidone/pharmacology , Wakefulness
3.
Psychopharmacology (Berl) ; 233(6): 961-72, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26660447

ABSTRACT

RATIONALE: There is significant interest in the NMDA receptor antagonist ketamine due to its efficacy in treating depressive disorders and its induction of psychotic-like symptoms that make it a useful tool for modeling psychosis. OBJECTIVE: The present study extends the successful development of an apparatus and methodology to conduct pharmacological MRI studies in awake rhesus monkeys in order to evaluate the CNS effects of ketamine. METHODS: Functional MRI scans were conducted in four awake adult female rhesus monkeys during sub-anesthetic intravenous (i.v.) infusions of ketamine (0.345 mg/kg bolus followed by 0.256 mg/kg/h constant infusion) with and without risperidone pretreatment (0.06 mg/kg). Statistical parametric maps of ketamine-induced blood oxygenation level-dependent (BOLD) activation were obtained with appropriate general linear regression models (GLMs) incorporating motion and hemodynamics of ketamine infusion. RESULTS: Ketamine infusion induced and sustained robust BOLD activation in a number of cortical and subcortical regions, including the thalamus, cingulate gyrus, and supplementary motor area. Pretreatment with the antipsychotic drug risperidone markedly blunted ketamine-induced activation in many brain areas. CONCLUSIONS: The results are remarkably similar to human imaging studies showing ketamine-induced BOLD activation in many of the same brain areas, and pretreatment with risperidone or another antipsychotic blunting the ketamine response to a similar extent. The strong concordance of the functional imaging data in humans with these results from nonhuman primates highlights the translational value of the model and provides an excellent avenue for future research examining the CNS effects of ketamine. This model may also be a useful tool for evaluating the efficacy of novel antipsychotic drugs.


Subject(s)
Brain/drug effects , Excitatory Amino Acid Antagonists/pharmacology , Ketamine/pharmacology , Animals , Antipsychotic Agents/pharmacology , Brain/physiology , Female , Macaca mulatta , Magnetic Resonance Imaging/methods , Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors , Risperidone/pharmacology , Wakefulness/drug effects
4.
Biochem Biophys Res Commun ; 384(2): 144-8, 2009 Jun 26.
Article in English | MEDLINE | ID: mdl-19393625

ABSTRACT

The metabolism of 1alpha,25-dihydroxyvitamin D2 (1alpha,25(OH)2D2) by human CYP24A1 was examined using the recombinant enzyme expressed in Escherichia coli cells. HPLC analysis revealed that human CYP24A1 produces at least 10 metabolites, while rat CYP24A1 produces only three metabolites, indicating a remarkable species-based difference in the CYP24A1-dependent metabolism of 1alpha,25(OH)2D2 between humans and rats. LC-MS analysis and periodate treatment of the metabolites strongly suggest that human CYP24A1 converts 1alpha,25(OH)2D2 to 1alpha,24,25,26(OH)4D2, 1alpha,24,25,28(OH)4D2, and 24-oxo-25,26,27-trinor-1alpha(OH)D2 via 1alpha,24,25(OH)3D2. These results indicate that human CYP24A1 catalyzes the C24-C25 bond cleavage of 1alpha,24,25(OH)2D2, which is quite effective in the inactivation of the active form of vitamin D2. The combination of hydroxylation at multiple sites and C-C bond cleavage could form a large number of metabolites. Our findings appear to be useful to predict the metabolism of vitamin D2 and its analogs in the human body.


Subject(s)
Cholestanetriol 26-Monooxygenase/metabolism , Vitamin D/analogs & derivatives , Humans , Vitamin D/chemistry , Vitamin D/metabolism
5.
Drug Metab Dispos ; 35(9): 1482-8, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17553915

ABSTRACT

Our previous study demonstrated that 25-hydroxy-19-nor-vitamin D(3) [25(OH)-19-nor-D(3)] inhibited the proliferation of immortalized noncancerous PZ-HPV-7 prostate cells similar to 1 alpha,25-dihydroxyvitamin D(3) [1 alpha,25(OH)(2)D(3)], suggesting that 25(OH)-19-nor-D(3) might be converted to 1 alpha,25-dihydroxy-19-nor-vitamin D(3) [1 alpha,25(OH)(2)-19-nor-D(3)] by CYP27B1 before exerting its antiproliferative activity. Using an in vitro cell-free model to study the kinetics of CYP27B1-dependent 1 alpha-hydroxylation of 25(OH)-19-nor-D(3) and 25-hydroxyvitamin D(3) [25(OH)D(3)] and CYP24A1-dependent hydroxylation of 1 alpha,25(OH)-19-nor-D(3) and 1 alpha,25(OH)(2)D(3), we found that k(cat)/K(m) for 1 alpha-hydroxylation of 25(OH)-19-nor-D(3) was less than 0.1% of that for 25(OH)D(3), and the k(cat)/K(m) value for 24-hydroxylation was not significantly different between 1 alpha,25(OH)(2)-19-nor-D(3) and 1 alpha,25(OH)(2)D(3). The data suggest a much slower formation and a similar rate of degradation of 1 alpha,25(OH)(2)-19-nor-D(3) compared with 1 alpha,25(OH)(2)D(3). We then analyzed the metabolites of 25(OH)D(3) and 25(OH)-19-nor-D(3) in PZ-HPV-7 cells by high-performance liquid chromatography. We found that a peak that comigrated with 1 alpha,25(OH)(2)D(3) was detected in cells incubated with 25(OH)D(3), whereas no 1 alpha,25(OH)(2)-19-nor-D(3) was detected in cells incubated with 25(OH)-19-nor-D(3). Thus, the present results do not support our previous hypothesis that 25(OH)-19-nor-D(3) is converted to 1 alpha,25(OH)(2)-19-nor-D(3) by CYP27B1 in prostate cells to inhibit cell proliferation. We hypothesize that 25(OH)-19-nor-D(3) by itself may have a novel mechanism to activate vitamin D receptor or it is metabolized in prostate cells to an unknown metabolite with antiproliferative activity without 1 alpha-hydroxylation. Thus, the results suggest that 25(OH)-19-nor-D(3) has potential as an attractive agent for prostate cancer therapy.


Subject(s)
25-Hydroxyvitamin D3 1-alpha-Hydroxylase/metabolism , Calcitriol/analogs & derivatives , Cholecalciferol/metabolism , Cytochrome P-450 Enzyme System/metabolism , 25-Hydroxyvitamin D3 1-alpha-Hydroxylase/genetics , Animals , Calcitriol/metabolism , Carbon Monoxide/metabolism , Cattle , Cell Line , Cell Proliferation/drug effects , Cholecalciferol/pharmacology , Chromatography, High Pressure Liquid , Cytochrome P-450 Enzyme System/genetics , Escherichia coli/metabolism , Humans , Hydroxylation , Kinetics , Male , Models, Molecular , Plasmids/genetics , Prostate/cytology , Prostate/metabolism , Steroid Hydroxylases , Thymus Gland/metabolism , Vitamin D3 24-Hydroxylase
6.
Mol Pharmacol ; 70(1): 120-8, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16617161

ABSTRACT

Our previous studies revealed the species-based difference of CYP24A1-dependent vitamin D metabolism. Although human CYP24A1 catalyzes both C-23 and C-24 oxidation pathways, rat CYP24A1 shows almost no C-23 oxidation pathway. We tried to identify amino acid residues that cause the species-based difference by site-directed mutagenesis. In the putative substrate-binding regions, amino acid residue of rat CYP24A1 was converted to the corresponding residue of human CYP24A1. Among eight mutants examined, T416M and I500T showed C-23 oxidation pathway. In addition, the mutant I500F showed quite a different metabolism of 1alpha,25-dihydroxyvitamin D3 [1alpha,25(OH)2D3] from both human and rat CYP24A1. These results strongly suggest that the amino acid residues at positions 416 and 500 play a crucial role in substrate binding and greatly affect substrate orientation. A three-dimensional model of CYP24A1 indicated that the A-ring and triene part of 1alpha,25(OH)2D3 could be located close to amino acid residues at positions 416 and 500, respectively. Our findings provide useful information for the development of new vitamin D analogs for clinical use.


Subject(s)
Mutagenesis, Site-Directed , Steroid Hydroxylases/metabolism , Amino Acid Sequence , Amino Acid Substitution/genetics , Amino Acids/genetics , Amino Acids/metabolism , Animals , Calcitriol/metabolism , Catalytic Domain/genetics , Chromatography, High Pressure Liquid , Escherichia coli/genetics , Gene Expression Regulation, Enzymologic , Humans , Isoleucine/genetics , Isoleucine/metabolism , Mass Spectrometry , Models, Molecular , Molecular Sequence Data , Mutant Proteins/chemistry , Mutant Proteins/genetics , Mutant Proteins/metabolism , Protein Structure, Tertiary , Rats , Sequence Homology, Amino Acid , Species Specificity , Steroid Hydroxylases/chemistry , Steroid Hydroxylases/genetics , Structure-Activity Relationship , Threonine/genetics , Threonine/metabolism , Vitamin D3 24-Hydroxylase
7.
Biochemistry ; 45(14): 4405-12, 2006 Apr 11.
Article in English | MEDLINE | ID: mdl-16584176

ABSTRACT

A molecular modeling study of CYP27B1 suggests that Arg458 of mouse CYP27B1 is involved in interaction with adrenodoxin (ADX). Thus, we generated CYP27B1 mutants R458K and R458Q and revealed their enzymatic properties. Substrate-induced difference spectra and K(m) values for 1alpha-hydroxylation of 25(OH)D3 indicate that the replacement of Arg458 with Lys or Gln does not affect substrate binding. However, these mutants showed remarkable decreases of both kcat values and the ratio of product formation to NADPH oxidation (coupling efficiency). A high K(m) value of R458Q for ADX concentration and a decrease of rate constant of the first electron transfer seem reasonable considering that the conversion from Arg to noncharged Gln abolishes salt-bridge formation with the acidic residue of ADX. On the other hand, R458K showed atypical kinetics for ADX concentration with Hill's constant of 2.0 and high catalytic activity at high ADX concentration by increase of coupling efficiency. These results suggest that conformational change of R458K by binding the two ADX molecules is essential for 1alpha-hydroxylation of 25(OH)D3. On the other hand, binding one ADX molecule is sufficient for the conformational change of the wild-type CYP27B1, judging from its Michaelis-Menten-type kinetics for ADX concentration with high coupling efficiency. These results suggest that ADX functions as an effector for the oxygen transfer reaction in addition to being an electron donor for CYP27B1.


Subject(s)
25-Hydroxyvitamin D3 1-alpha-Hydroxylase/metabolism , Adrenodoxin/metabolism , Arginine/physiology , 25-Hydroxyvitamin D3 1-alpha-Hydroxylase/genetics , Amino Acid Sequence , Animals , Calcifediol/metabolism , Ferredoxin-NADP Reductase/metabolism , Hydroxylation , Kinetics , Mice , Mitochondria/enzymology , Models, Molecular , NADP/metabolism , Oxidation-Reduction , Protein Conformation , Sequence Alignment , Spectrophotometry
8.
J Biol Chem ; 280(34): 30511-6, 2005 Aug 26.
Article in English | MEDLINE | ID: mdl-15972816

ABSTRACT

We previously reported the three-dimensional structure of human CYP27B1 (25-hydroxyvitamin D3 1alpha-hydroxylase) constructed by homology modeling. Using the three-dimensional model we studied the docking of the substrate, 25-hydroxyvitamin D3, into the substrate binding pocket of CYP27B1. In this study, we focused on the amino acid residues whose point mutations cause vitamin D-dependent rickets type 1, especially unconserved residues among mitochondrial CYPs such as Gln65 and Thr409. Recently, we successfully overexpressed mouse CYP27B1 by using a GroEL/ES co-expression system. In a mutation study of mouse CYP27B1 that included spectroscopic analysis, we concluded that in a 1alpha-hydroxylation process, Ser408 of mouse CYP27B1 corresponding to Thr409 of human CYP27B1 forms a hydrogen bond with the 25-hydroxyl group of 25-hydroxyvitamin D3. This is the first report that shows a critical amino acid residue recognizing the 25-hydroxyl group of the vitamin D3.


Subject(s)
25-Hydroxyvitamin D3 1-alpha-Hydroxylase/chemistry , Calcifediol/metabolism , Rickets/genetics , Vitamin D/metabolism , Amino Acid Sequence , Animals , Blotting, Western , Cholecalciferol/chemistry , Escherichia coli/metabolism , Glutamine/chemistry , Humans , Hydrogen Bonding , Kinetics , Mice , Models, Chemical , Models, Molecular , Molecular Sequence Data , Mutation , Oligonucleotides/chemistry , Plasmids/metabolism , Point Mutation , Polymerase Chain Reaction , Protein Binding , Protein Conformation , Protein Folding , Protein Structure, Tertiary , Recombinant Proteins/chemistry , Sequence Homology, Amino Acid , Spectrophotometry , Substrate Specificity , Threonine/chemistry , Time Factors
9.
Biochem Biophys Res Commun ; 323(2): 505-11, 2004 Oct 15.
Article in English | MEDLINE | ID: mdl-15369780

ABSTRACT

The expression of mouse CYP27B1 in Escherichia coli has been dramatically enhanced by coexpression of GroEL/ES. To reveal the enzymatic properties of CYP27B1, we measured its hydroxylation activity toward vitamin D3 and 1alpha-hydroxyvitamin D3 (1alpha(OH)D3) in addition to the physiological substrate 25(OH)D3. Surprisingly, CYP27B1 converted vitamin D3 to 1alpha,25(OH)D3. Both 1alpha-hydroxylation activity toward vitamin D3, and 25-hydroxylation activity toward 1alpha(OH)D3 were observed. The Km and Vmax values for 25-hydroxylation activity toward 1alpha(OH)D3 were estimated to be 1.7 microM and 0.51 mol/min/mol P450, respectively, while those for 1alpha-hydroxylation activity toward 25(OH)D3 were 0.050 microM and 2.73 mol/min/mol P450, respectively. Note that the substrate must be fixed in the opposite direction in the substrate-binding pocket of CYP27B1 between 1alpha-hydroxylation and 25-hydroxylation. Based on these results and the fact that human CYP27A1 and Streptomyces CYP105A1 also convert vitamin D3 to 1alpha,25(OH)D3, 1alpha-hydroxylation, and 25-hydroxylation of vitamin D3 appear to be closely linked together.


Subject(s)
25-Hydroxyvitamin D3 1-alpha-Hydroxylase/biosynthesis , 25-Hydroxyvitamin D3 1-alpha-Hydroxylase/chemistry , Chaperonin 10/biosynthesis , Chaperonin 60/biosynthesis , Protein Engineering/methods , 25-Hydroxyvitamin D3 1-alpha-Hydroxylase/genetics , Animals , Chaperonin 10/chemistry , Chaperonin 10/genetics , Chaperonin 60/chemistry , Chaperonin 60/genetics , Chaperonins/biosynthesis , Chaperonins/chemistry , Chaperonins/genetics , Cloning, Molecular/methods , Enzyme Activation , Escherichia coli , Genetic Enhancement , Mice , Molecular Weight , Recombinant Proteins/biosynthesis , Recombinant Proteins/chemistry , Substrate Specificity
SELECTION OF CITATIONS
SEARCH DETAIL
...